Summary
Global Markets Direct’s, ‘Sanofi Pasteur SA - Product Pipeline Review - 2016’, provides an overview of the Sanofi Pasteur SA’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Sanofi Pasteur SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Sanofi Pasteur SA
- The report provides overview of Sanofi Pasteur SA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sanofi Pasteur SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sanofi Pasteur SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Sanofi Pasteur SA’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sanofi Pasteur SA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sanofi Pasteur SA’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Sanofi Pasteur SA Snapshot 6
Sanofi Pasteur SA Overview 6
Key Information 6
Key Facts 6
Sanofi Pasteur SA - Research and Development Overview 7
Key Therapeutic Areas 7
Sanofi Pasteur SA - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Sanofi Pasteur SA - Pipeline Products Glance 15
Sanofi Pasteur SA - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Filing rejected/Withdrawn Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Sanofi Pasteur SA - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Sanofi Pasteur SA - Early Stage Pipeline Products 20
Discovery Products/Combination Treatment Modalities 20
Sanofi Pasteur SA - Drug Profiles 21
dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
influenza [serotypes A, B] (split virion, tetravalent) vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
(diphtheria + tetanus + pertussis (acellular)) vaccine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Clostridium difficile vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ETEC vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
influenza [strain A/H7N9] vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
rabies [strain Wistar PM/WI 38-1503-3M] vaccine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
tuberculosis vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VCP-2438 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
HSV-529 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pneumococcal (trivalent) vaccine 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Streptococcus pneumonia vaccine 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VCP-2292 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
infectious disease vaccine 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
influenza vaccine 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Sanofi Pasteur SA - Pipeline Analysis 45
Sanofi Pasteur SA - Pipeline Products by Target 45
Sanofi Pasteur SA - Pipeline Products by Route of Administration 46
Sanofi Pasteur SA - Pipeline Products by Molecule Type 47
Sanofi Pasteur SA - Recent Pipeline Updates 48
Sanofi Pasteur SA - Dormant Projects 54
Sanofi Pasteur SA - Discontinued Pipeline Products 55
Discontinued Pipeline Product Profiles 55
meningitis [serotype B] vaccine 55
Sanofi Pasteur SA - Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59
List of Tables
Sanofi Pasteur SA, Key Information 6
Sanofi Pasteur SA, Key Facts 6
Sanofi Pasteur SA - Pipeline by Indication, 2016 8
Sanofi Pasteur SA - Pipeline by Stage of Development, 2016 10
Sanofi Pasteur SA - Monotherapy Products in Pipeline, 2016 11
Sanofi Pasteur SA - Combination Treatment Modalities in Pipeline, 2016 12
Sanofi Pasteur SA - Partnered Products in Pipeline, 2016 13
Sanofi Pasteur SA - Partnered Products/ Combination Treatment Modalities, 2016 14
Sanofi Pasteur SA - Pre-Registration, 2016 15
Sanofi Pasteur SA - Filing rejected/Withdrawn, 2016 16
Sanofi Pasteur SA - Phase III, 2016 17
Sanofi Pasteur SA - Phase II, 2016 18
Sanofi Pasteur SA - Phase I, 2016 19
Sanofi Pasteur SA - Discovery, 2016 20
Sanofi Pasteur SA - Pipeline by Target, 2016 45
Sanofi Pasteur SA - Pipeline by Route of Administration, 2016 46
Sanofi Pasteur SA - Pipeline by Molecule Type, 2016 47
Sanofi Pasteur SA - Recent Pipeline Updates, 2016 48
Sanofi Pasteur SA - Dormant Developmental Projects,2016 54
Sanofi Pasteur SA - Discontinued Pipeline Products, 2016 55
Sanofi Pasteur SA, Other Locations 56
Sanofi Pasteur SA, Subsidiaries 57
List of Figures
Sanofi Pasteur SA - Pipeline by Top 10 Indication, 2016 8
Sanofi Pasteur SA - Pipeline by Stage of Development, 2016 10
Sanofi Pasteur SA - Monotherapy Products in Pipeline, 2016 11
Sanofi Pasteur SA - Combination Treatment Modalities in Pipeline, 2016 12
Sanofi Pasteur SA - Partnered Products in Pipeline, 2016 13
Sanofi Pasteur SA - Pipeline by Target, 2016 45
Sanofi Pasteur SA - Pipeline by Route of Administration, 2016 46
Sanofi Pasteur SA - Pipeline by Molecule Type, 2016 47
